The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of Zemplar as it is prescribed in the normal clinical setting and according to the approved Summary of Product Characteristics for the treatment of secondary hyperparathyroidism in hemodialysis patients in Greece.
The primary objective of this study is to evaluate the safety of Zemplar® in the treatment of Secondary hyperparathyroidism (iParathormone\>300 pg/mL) in subjects on hemodialysis treated in conditions of usual clinical care. The primary safety endpoints of this study are to evaluate the safety of Zemplar by recording the number of hospitalizations and days hospitalized. A secondary efficacy endpoint will be the proportion of subjects achieving therapeutic success. Therapeutic success with Zemplar® will be defined as: * 40% reduction in the base iPTH level is achieved, and/or; * serum iParathormone level \< 300 pg/mL. Additional secondary endpoints are the incidence (proportion of patients) of clinically meaningful hypercalcemia (defined as corrected serum calcium (Ca) \> 11.0 mg/dL taken at 2 consecutive measurements), hyperphosphatemia (defined as serum phosphorous (P)\>6.5 mg/dL taken at 2 consecutive measurements), and elevated Ca x P product (defined as serum Ca x P\>65 mg\^2/dL\^2 taken at 2 consecutive measurements). Safety also will be assessed through adverse event monitoring and evaluation of laboratory variables and vital signs.
Study Type
OBSERVATIONAL
Enrollment
237
Site Reference ID/Investigator# 32055
Athens, Greece
Site Reference ID/Investigator# 32050
Athens, Greece
Safety Evaluation of Paricalcitol by Recording the Number of Hospitalizations
The number of participants who were hospitalized during the study and the number of hospitalizations are summarized.
Time frame: Baseline to Month 24 Visit
Safety Evaluation of Paricalcitol by Recording the Number of Days Hospitalized
The mean (average) number of days hospitalized per participant for those hospitalized during the study.
Time frame: Baseline to Month 24 Visit
The Proportion of Patients Achieving Therapeutic Success (Defined as 40% Reduction in Base Parathormone Level and/or Parathormone Level <300 pg/ml)
Therapeutic success of paricalcitol treatment was defined as a 40% decrease from the baseline measurement in the level of intact parathyroid hormone (also known as iPTH or parathormone) and/or a serum intact parathyroid hormone level less than 300 picograms per milliliter (pg/mL) for at least 2 consecutive available measurements during the 24-month follow-up period.
Time frame: Baseline to Month 24 Visit
The Incidence of Clinically Significant Hypercalcemia
The number of participants with clinically significant hypercalcemia (too much calcium in the blood), defined as a corrected serum calcium level greater than 11.0 milligrams per deciliter (mg/dL) at 2 consecutive measurements.
Time frame: Baseline to Month 24 Visit
The Incidence of Clinically Significant Hyperphosphatemia
The number of participants with clinically significant hyperphosphatemia (too much phosphorous in the blood), defined as serum phosphorous levels greater than 6.5 milligrams per deciliter (mg/dL) at 2 consecutive measurements.
Time frame: Baseline to Month 24 Visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site Reference ID/Investigator# 32051
Athens, Greece
Site Reference ID/Investigator# 32049
Athens, Greece
Site Reference ID/Investigator# 5283
Athens, Greece
Site Reference ID/Investigator# 32056
Chalcis, Greece
Site Reference ID/Investigator# 32057
Chania, Greece
Site Reference ID/Investigator# 32077
Cholargós, Greece
Site Reference ID/Investigator# 32058
Drama, Greece
Site Reference ID/Investigator# 32076
Katerini, Greece
...and 9 more locations
The Incidence of Clinically Significant Elevation of Calcium-phosphorous (Ca x P) Product
The number of participants with clinically significant levels of calcium-phosphorous product (Ca x P), defined as serum calcium-phosphorous product levels greater than 65 milligrams squared per deciliters squared (mg\^2/dL\^2) at 2 consecutive measurements.
Time frame: Baseline to Month 24 Visit
To Estimate the Incidence of (S)AEs/(S)ADRs
The number of adverse events, serious adverse events (including death), adverse drug reactions, and serious adverse drug reactions experienced by participants during the study are summarized. Adverse events include any events reported regardless of whether or not they were considered related to the study drug. Adverse drug reactions include events where a causal relationship between the drug and the occurence of the event is suspected. For additional details see the Reported Adverse Events section.
Time frame: Baseline to Month 24 Visit